ArticleBMC cardiovascular disorders2026
Occlusion effects, safety, and clinical prognosis of Watchman and LAmbre occluders in left atrial appendage closure.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study preformed to investigate the safety and effectiveness of the Watchman and LAmbre occluders in left atrial appendage closure (LAAC) for the prevention of thrombosis and stroke in patients with atrial fibrillation (AF).
methodsA retrospective analysis was conducted on 93 patients with nonvalvular atrial fibrillation (NVAF) who underwent LAAC at Northern Jiangsu People's Hospital from January 2020 to February 2023. Of these, 48 were implanted with the Watchman occluder and 45 with the LAmbre occluder.
resultsDifferences in LAA opening diameter and left atrial diameter between groups were statistically significant (P < 0.001, P = 0.012). The complete occlusion rate of the LAA in the Watchman group was 45.83% (22/48), compared to 24.44% (11/45) in the LAmbre group, with a significant difference between groups (P = 0.031 < 0.05). Neither group experienced any transient ischemic attacks, cardiac tamponade, or deaths during the perioperative period. Three-month postoperative CTA check-ups showed no displacement or detachment of occluders in either group. The incidence of residual shunt measured by CTA was significantly lower in the Watchman group than in the LAmbre group. The most common occurrence in both groups was a 1-3 mm peri-device leak (PDL) at the edge of the occluders. One major PDL (≥ 5 mm) occurred in the LAmbre group. Both groups had device-related thrombosis (DRT) on the atrial side of the occluder, all of which were in patients with PDL and disappeared after 3 months of systemic anticoagulation therapy.
conclusionBoth the LAmbre and Watchman occluders show high safety and clinical prognosis in LAAC treatment for AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.